| Literature DB >> 20358582 |
Anélia Horvath1, Jérôme Bertherat, Lionel Groussin, Marine Guillaud-Bataille, Kitman Tsang, Laure Cazabat, Rosella Libé, Elaine Remmers, Fernande René-Corail, Fabio Rueda Faucz, Eric Clauser, Alain Calender, Xavier Bertagna, J Aidan Carney, Constantine A Stratakis.
Abstract
PRKAR1A encodes the regulatory subunit type 1-alpha (RIalpha) of the cyclic adenosine monophosphate (cAMP)-dependent protein kinase (PKA). Inactivating PRKAR1A mutations are known to be responsible for the multiple neoplasia and lentiginosis syndrome Carney complex (CNC). To date, at least 117 pathogenic variants in PRKAR1A have been identified (online database: http://prkar1a.nichd.nih.gov). The majority are subject to nonsense mediated mRNA decay (NMD), leading to RIalpha haploinsufficiency and, as a result, activated cAMP signaling. Recently, it became apparent that CNC may be caused not only by RIalpha haploinsufficiency, but also by the expression of altered RIalpha protein, as proven by analysis of expressed mutations in the gene, consisting of amino acid substitutions and in-frame genetic alterations. In addition, a new subgroup of mutations that potentially escape NMD and result in CNC through altered (rather than missing) protein has been analyzed-these are frame-shifts in the 3' end of the coding sequence that shift the stop codon downstream of the normal one. The mutation detection rate in CNC patients is recently estimated at above 60%; PRKAR1A mutation-negative CNC patients are characterized by significant phenotypic heterogeneity. In this report, we present a comprehensive analysis of all presently known PRKAR1A sequence variations and discuss their molecular context and clinical phenotype. Published 2010 Wiley-Liss, Inc.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20358582 PMCID: PMC2936101 DOI: 10.1002/humu.21178
Source DB: PubMed Journal: Hum Mutat ISSN: 1059-7794 Impact factor: 4.878